MiMedx Group, Inc (NASDAQ:MDXG) Receives $9.60 Average Price Target from Analysts

MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $9.60.

MDXG has been the subject of several research reports. Citizens Jmp started coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Lake Street Capital dropped their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Finally, Citigroup began coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating for the company.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently modified their holdings of the business. World Investment Advisors purchased a new stake in MiMedx Group during the 4th quarter valued at about $173,000. Virtu Financial LLC purchased a new position in MiMedx Group in the 4th quarter worth approximately $78,000. Invesco Ltd. lifted its stake in MiMedx Group by 5.9% in the 4th quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock worth $574,000 after purchasing an additional 4,708 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in shares of MiMedx Group by 26.0% during the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock worth $316,000 after purchasing an additional 9,614 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in shares of MiMedx Group by 33.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock worth $141,000 after purchasing an additional 5,236 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Stock Performance

MDXG opened at $3.94 on Friday. The firm’s fifty day simple moving average is $4.90 and its two-hundred day simple moving average is $6.22. MiMedx Group has a 52-week low of $3.92 and a 52-week high of $7.99. The company has a market cap of $585.37 million, a price-to-earnings ratio of 12.31 and a beta of 1.60. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $118.10 million during the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. Equities analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.